Does EmblemHealth Cover Eliquis?

How EmblemHealth Formularies Handle Eliquis

Most EmblemHealth plans include Eliquis on their formulary as a preferred-brand medication, which places it on Tier 3 in the insurer's standard tiering structure. This means the drug is covered but carries a higher copay than generic alternatives like warfarin. EmblemHealth operates multiple plan types across New York, including HMO, PPO, EPO, and Medicare Advantage products, and formulary placement can shift between plan years.

Commercial Plan Coverage

On EmblemHealth commercial plans, Eliquis typically sits on the preferred-brand tier. The FDA-approved prescribing information for apixaban lists the standard dose as 5 mg twice daily for atrial fibrillation, which translates to 60 tablets per month [1]. EmblemHealth's quantity limits usually align with this dosing. Copays on commercial plans tend to fall between $35 and $90 for a 30-day supply, though the exact amount depends on your benefit design and whether you have reached your deductible.

Medicare Advantage Plans

EmblemHealth's Medicare Advantage formularies also cover Eliquis, but Part D cost-sharing rules apply. Under the 2025 Medicare Part D redesign, out-of-pocket prescription costs are capped at $2,000 annually [2]. For Medicare Advantage enrollees taking Eliquis, this cap may significantly reduce total yearly spending on the drug. Eliquis often falls on Tier 3 or Tier 4 of Medicare formularies, which means coinsurance of 25% to 33% before reaching the catastrophic coverage phase.

Checking Your Specific Plan

The most reliable way to confirm coverage is to log into your EmblemHealth member portal or call the number on the back of your insurance card. Formularies update annually, and mid-year changes can occur. Your plan's Summary of Benefits and Coverage (SBC) document will list the exact tier and cost-sharing for Eliquis.

Why Eliquis Is Commonly Prescribed

Eliquis belongs to the direct oral anticoagulant (DOAC) class and received FDA approval in December 2012 for reducing stroke risk in patients with nonvalvular atrial fibrillation [3]. It has since gained additional approvals for treating deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as preventing recurrent VTE.

Clinical Trial Evidence

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily with warfarin in patients with atrial fibrillation. Apixaban reduced stroke or systemic embolism by 21% relative to warfarin (hazard ratio 0.79, 95% CI 0.66 to 0.95) and lowered major bleeding by 31% (HR 0.69, 95% CI 0.60 to 0.80) [4]. All-cause mortality was also lower with apixaban (3.52% vs. 3.94% per year). These results established apixaban as a first-line anticoagulant option for atrial fibrillation.

Guideline Recommendations

The 2023 ACC/AHA/ACCP/HRS guideline for atrial fibrillation management recommends DOACs, including apixaban, over warfarin for most patients with nonvalvular AF who require anticoagulation [5]. The guideline gives apixaban a Class I recommendation (Level of Evidence A), meaning there is strong evidence supporting its use. The American College of Chest Physicians (ACCP) also recommends DOACs as preferred agents for VTE treatment over vitamin K antagonists [6].

What You Will Pay Out of Pocket

Your actual cost for Eliquis through EmblemHealth depends on several variables: your plan tier, deductible status, and whether you use a copay assistance program.

Copay Estimates by Plan Type

For EmblemHealth HMO and EPO plans, expect a fixed copay between $35 and $90 per fill. PPO plans may use coinsurance instead, meaning you pay a percentage of the drug's negotiated price. The average wholesale price of Eliquis is approximately $600 per month for 60 tablets of the 5 mg strength [7]. A 25% coinsurance rate before deductible would mean roughly $150 out of pocket per fill, though most plans negotiate substantially lower rates.

Manufacturer Copay Card

Bristol-Myers Squibb and Pfizer offer a copay savings program for commercially insured patients that can reduce the out-of-pocket cost to as low as $10 per month [8]. This card cannot be used with Medicare, Medicaid, or other federal insurance programs. Eligible patients can save up to $6,400 per year through the program.

Strategies to Lower Your Cost

If Eliquis remains expensive on your EmblemHealth plan, consider these approaches. First, ask your prescriber about a formulary exception request if the drug is on a non-preferred tier. Second, use a 90-day mail-order pharmacy through EmblemHealth's pharmacy benefit, which often provides a lower per-day cost. Third, compare pricing at different in-network pharmacies, as costs can vary by $20 to $50 per fill within the same network.

Prior Authorization and Step Therapy Requirements

EmblemHealth may require prior authorization for Eliquis in certain clinical scenarios. PA requirements are more common on Medicare Advantage plans than on commercial plans.

When Prior Authorization Applies

Prior authorization for Eliquis is most frequently required when the drug is prescribed for off-label indications or when the requested dose differs from FDA-labeled dosing [9]. For standard indications (nonvalvular AF, DVT/PE treatment), many EmblemHealth commercial plans do not require PA. However, plan designs change annually, so confirming with the pharmacy benefit manager before filling is a good practice.

The Appeal Process

If EmblemHealth denies coverage or applies an unexpected restriction, you have the right to appeal. New York State insurance regulations require EmblemHealth to process standard appeals within 30 days and expedited appeals within 72 hours. Your prescribing physician can submit a letter of medical necessity citing clinical trial evidence and guideline recommendations to support the appeal.

Step Therapy Considerations

Step therapy (requiring you to try a less expensive drug first) is uncommon for Eliquis on EmblemHealth commercial plans. However, some plans may prefer warfarin as a first-line agent due to its substantially lower cost. The AUGUSTUS trial (N=4,614) demonstrated that apixaban was associated with less bleeding than warfarin in AF patients undergoing PCI or with acute coronary syndrome, which can support bypassing step therapy if warfarin poses a higher bleeding risk for you [10].

Alternatives to Eliquis on EmblemHealth Plans

If cost or coverage barriers make Eliquis impractical, several therapeutic alternatives exist within EmblemHealth formularies.

Warfarin

Warfarin is a generic vitamin K antagonist that costs as little as $4 per month. It requires regular INR monitoring (typically every 2 to 4 weeks) and has more drug-food interactions than DOACs. The RE-LY trial (N=18,113) and ARISTOTLE trial both demonstrated that DOACs have advantages over warfarin in bleeding risk, but warfarin remains a clinically appropriate choice for many patients, particularly those with mechanical heart valves where DOACs are contraindicated [11].

Rivaroxaban (Xarelto)

Rivaroxaban is another DOAC that EmblemHealth typically covers. The ROCKET AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention in AF (HR 0.88, 95% CI 0.75 to 1.03) [12]. Rivaroxaban has the convenience of once-daily dosing for AF (20 mg with the evening meal), compared to apixaban's twice-daily schedule. Its formulary tier on EmblemHealth plans may differ from Eliquis, so checking both is worthwhile.

Edoxaban (Savaysa)

Edoxaban is a less commonly prescribed DOAC. The ENGAGE AF-TIMI 48 trial (N=21,105) demonstrated noninferiority to warfarin for stroke prevention, with lower rates of bleeding and cardiovascular death [13]. Edoxaban is sometimes placed on a lower formulary tier than apixaban, which could translate to a smaller copay.

Safety Monitoring While Taking Eliquis

Regardless of insurance coverage, patients on Eliquis need ongoing clinical monitoring. The drug does not require routine blood level testing (unlike warfarin), but periodic assessment is still necessary.

Renal Function

Apixaban is partially renally cleared, and the FDA label recommends dose reduction to 2.5 mg twice daily in patients who meet at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [14]. Renal function should be checked at baseline and at least annually thereafter. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend more frequent monitoring (every 3 to 6 months) in patients with eGFR <30 mL/min [15].

Bleeding Risk Assessment

Your provider should evaluate bleeding risk using a validated tool such as HAS-BLED at each visit. Signs of clinically significant bleeding include unexplained bruising, blood in urine or stool, prolonged bleeding from cuts, and hemoptysis. The ISTH definition of major bleeding includes a hemoglobin drop of 2 g/dL or greater, transfusion of 2 or more units of red blood cells, or bleeding into a critical site [16].

Drug Interactions

Apixaban is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Strong dual inhibitors of both pathways (such as ketoconazole, itraconazole, and ritonavir) can increase apixaban exposure and bleeding risk. The ACC Expert Consensus on DOACs recommends avoiding combined strong CYP3A4 and P-gp inhibitors with apixaban, or reducing the dose to 2.5 mg twice daily when co-administration is unavoidable [17].

How to Verify Your EmblemHealth Coverage

Getting a definitive answer about your Eliquis coverage takes about 10 minutes.

Three Steps to Confirm

Call EmblemHealth member services at the number on your card and ask for the pharmacy benefit team. Request the tier placement, copay or coinsurance amount, and any utilization management (PA, step therapy, quantity limits) for apixaban 5 mg tablets, quantity 60. Ask whether the manufacturer copay card can be applied at your pharmacy.

Pharmacy Benefit Manager Details

EmblemHealth contracts with pharmacy benefit managers (PBMs) that administer the drug formulary. Your PBM may differ based on your employer group or plan type. The PBM's formulary search tool (accessible through EmblemHealth's website) allows you to look up Eliquis by name and see its current coverage status, restrictions, and cost estimate for your specific benefit.